---
layout: ../../layouts/Article.astro
title: "Thymosin Alpha-1: The Immune-Boosting Peptide Approved in 35+ Countries"
description: "A complete guide to thymosin alpha-1 (Zadaxin), the immune-modulating peptide used for hepatitis, cancer support, and infections. Mechanism, dosing, research, and legal status."
image: /images/articles/thymosin-alpha-1.webp
date: 2026-02-15
category: "Peptide Guides"
tags: ["thymosin alpha-1", "immune system", "Zadaxin", "hepatitis B", "T-cells", "immune modulation", "peptides"]
author: "PeptideRundown Team"
---

# Thymosin Alpha-1: The Immune-Boosting Peptide Approved in 35+ Countries

Your thymus gland starts shrinking after puberty. By age 50, it's mostly fat.

That matters because the thymus is where your T-cells learn to fight. When it deteriorates, your immune system gets slower, weaker, and less precise. Thymosin alpha-1 is the peptide your thymus makes to keep things running.

And it turns out, you can inject it.

> **Key Takeaways**
>
> - **Thymosin alpha-1** is a 28-amino acid peptide naturally produced by the thymus gland
> - **Approved as Zadaxin** in over 35 countries for hepatitis B and as an immune adjuvant
> - **Activates dendritic cells and T-cells**, restoring immune surveillance without overstimulation
> - **Studied in hepatitis B/C, cancer immunotherapy, HIV, and COVID-19** with promising clinical results
> - **Not FDA-approved** in the United States, but available through compounding pharmacies and research suppliers

## What Is Thymosin Alpha-1?

Thymosin alpha-1 (Ta1) is a **28-amino acid peptide** originally isolated from thymic tissue in the 1970s by Allan Goldstein at George Washington University.

It's the primary active fraction of a crude preparation called thymosin fraction 5, which researchers had already shown could restore immune function in animals that had their thymus removed.

| Feature | Detail |
|---------|--------|
| **Type** | Endogenous immunomodulatory peptide |
| **Amino Acids** | 28 |
| **Molecular Weight** | 3,108 Da |
| **Origin** | Human thymus gland (synthetic versions used clinically) |
| **Brand Name** | Zadaxin (thymalfasin) |
| **Approved In** | 35+ countries (not the US) |

The synthetic version is called **thymalfasin**. It's identical to the naturally occurring peptide and has been manufactured by SciClone Pharmaceuticals (now part of Pharmanovia) since the 1990s.

For a deeper compound profile, check out the [thymosin alpha-1 overview on PeptideArc](https://peptidearc.com).

## How Thymosin Alpha-1 Works

Ta1 doesn't jack up your immune system the way a stimulant would. It's a modulator, not an accelerator. That distinction is critical.

### Dendritic Cell Activation

Dendritic cells are the scouts of your immune system. They detect threats, process them, and present the information to T-cells so the right response gets launched.

Ta1 acts on **toll-like receptors (TLR2 and TLR9)** on dendritic cells, priming them to recognize pathogens more effectively.

- **Increases antigen presentation** - dendritic cells become better at flagging threats
- **Promotes maturation** - immature dendritic cells develop into fully functional sentinels
- **Enhances cytokine signaling** - IL-12 and IFN-alpha production goes up, directing the immune response

([Romani et al., 2006](https://pubmed.ncbi.nlm.nih.gov/17052970/))

### T-Cell Differentiation and Activation

This is where Ta1 earned its name. It pushes immature T-cell precursors toward becoming functional, mature T-cells.

- **Increases CD4+ and CD8+ T-cell counts** - the workhorses of adaptive immunity
- **Promotes T-cell maturation markers** - upregulates CD2, CD3, CD4, and CD8 expression
- **Restores T-cell function in immunocompromised patients** - particularly in those with low baseline counts

([Tuthill et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20590374/))

> **Key Finding:** In patients with depressed immune function, Ta1 can increase T-cell counts by 30-60% within weeks of starting treatment.

### NK Cell Enhancement

Natural killer (NK) cells handle the first line of defense against viruses and tumor cells. Ta1 boosts their activity without requiring antigen-specific activation.

- **Increases NK cell cytotoxicity** - better at destroying infected and malignant cells
- **Upregulates NK cell markers** - CD56 and CD16 expression increases
- **Synergizes with interferon** - the combination is more effective than either alone

### The Modulation Difference

Here's what makes Ta1 different from drugs that simply crank up immune activity.

| Immune State | Ta1's Effect |
|-------------|-------------|
| **Suppressed immunity** | Boosts T-cell counts, restores function |
| **Normal immunity** | Minimal change, mild enhancement |
| **Overactive immunity** | Can reduce inflammatory cytokines |

Ta1 tends to normalize rather than push in one direction. This bidirectional activity is why researchers have studied it in both immunodeficiency and autoimmune contexts.

([Garaci, 2007](https://pubmed.ncbi.nlm.nih.gov/17267044/))

## Approved Uses: Zadaxin Around the World

Zadaxin (thymalfasin) has been approved in **over 35 countries**, primarily in Asia, Latin America, and parts of Europe.

### Hepatitis B

This is the primary approved indication. Chronic hepatitis B affects roughly **296 million people worldwide** (WHO, 2024), and standard interferon therapy works in only a subset of patients.

Ta1 was approved as a treatment for chronic hepatitis B, either as monotherapy or combined with interferon-alpha.

| Trial Parameter | Detail |
|----------------|--------|
| **Patients** | 435 chronic HBV carriers across multiple RCTs |
| **Duration** | 6-12 months of treatment |
| **Design** | Randomized, controlled, some double-blind |

**Results from pooled analysis:**

| Treatment | Sustained Viral Response |
|-----------|------------------------|
| **Ta1 alone** | 26-36% |
| **Interferon-alpha alone** | 20-28% |
| **Ta1 + Interferon-alpha** | 40-50% |
| **Placebo** | 10-15% |

The combination with interferon consistently outperformed either agent alone.

([Iino et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15826557/))

> **Key Finding:** Ta1's sustained response rates continued to improve even after treatment ended, with viral clearance rates increasing at 12-month follow-up compared to end-of-treatment measurements.

### Hepatitis C

Before direct-acting antivirals (DAAs) changed the hepatitis C treatment space, Ta1 was studied as an adjunct to interferon and ribavirin therapy.

- **Improved sustained virological response (SVR)** in combination regimens
- **Better tolerated** than interferon dose escalation
- **Particularly effective in non-responders** to prior interferon therapy

([Kullavanuava et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11509370/))

With modern DAAs achieving 95%+ cure rates, Ta1's role in hepatitis C has diminished. But it remains relevant in resource-limited settings where DAAs aren't available.

### Immune Adjuvant for Vaccines

Several countries approve Ta1 as a vaccine adjuvant, particularly for:

- **Influenza vaccination in the elderly** - improves seroconversion rates in immunosenescent patients
- **Hepatitis B vaccination in immunocompromised patients** - dialysis patients and those who fail standard vaccination

([Gravenstein et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19651075/))

## Cancer Research

Ta1 has been studied extensively as an **adjunct to chemotherapy and immunotherapy**, not as a standalone cancer treatment.

The rationale is straightforward: chemotherapy suppresses the immune system. Ta1 may help restore immune function during and after treatment, improving outcomes and reducing infection risk.

### Clinical Data in Cancer

| Cancer Type | Intervention | Finding |
|------------|-------------|---------|
| **Hepatocellular carcinoma** | Ta1 + TACE | Improved 1-year survival vs TACE alone |
| **Non-small cell lung cancer** | Ta1 + chemotherapy | Improved T-cell counts, reduced infections |
| **Melanoma** | Ta1 + interferon + dacarbazine | Higher response rates vs chemo alone |
| **Gastric cancer** | Ta1 + chemotherapy | Reduced immunosuppression post-chemo |

([Garaci et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22316459/))

### Hepatocellular Carcinoma (Liver Cancer)

The strongest cancer data comes from liver cancer studies, which makes sense given Ta1's track record in hepatitis (a major cause of liver cancer).

A meta-analysis of **seven randomized trials** found that Ta1 combined with transarterial chemoembolization (TACE) significantly improved:

- **Overall survival at 1 and 2 years**
- **Recurrence-free survival**
- **CD4+/CD8+ T-cell ratios** during treatment

([Liu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27524894/))

> **Important:** Ta1 is not a cancer treatment on its own. The evidence supports it as a supportive agent that helps maintain immune function during conventional cancer therapy.

## COVID-19 Applications

When SARS-CoV-2 emerged, researchers noticed that severe COVID patients had dramatically reduced T-cell counts. That observation made Ta1 an obvious candidate.

### Early Clinical Evidence

A retrospective study from Wuhan examined **76 severe COVID-19 patients** and found that those who received Ta1 had:

- **Significantly lower mortality** (11.1% vs 30.0% in controls)
- **Restored CD4+ and CD8+ T-cell counts**
- **Reduced markers of organ damage** (LDH, creatine kinase)
- **Lower rates of secondary infection**

([Liu et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32425645/))

### Broader COVID Research

| Study | Patients | Key Finding |
|-------|----------|-------------|
| **Wuhan retrospective** | 76 severe cases | 63% relative mortality reduction |
| **Italian compassionate use** | 12 patients | T-cell count recovery within 7 days |
| **Multi-center Chinese** | 334 critical cases | Improved 28-day survival with Ta1 |

([Wu et al., 2020](https://pubmed.ncbi.nlm.nih.gov/33052324/))

The data is encouraging but largely retrospective. No large randomized controlled trial of Ta1 in COVID-19 has been completed as of early 2026.

> **Key Finding:** Ta1 appeared most effective in COVID patients with baseline lymphocyte counts below 0.5 x 10^9/L, suggesting its greatest benefit is in those with the most suppressed immune function.

## Sepsis and Critical Care

Beyond viral infections, Ta1 has shown promise in **sepsis**, where immune paralysis is a major driver of late-stage mortality.

A randomized trial of **361 patients with severe sepsis** found that Ta1:

- **Reduced 28-day mortality** from 35.0% to 26.0%
- **Improved HLA-DR expression** on monocytes (a marker of immune competence)
- **Decreased secondary infections** in the ICU setting

([Wu et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23787399/))

This is one of the larger and better-designed trials of Ta1 in any condition.

## Dosing

> **Important:** These are research-based protocols from clinical trials and approved prescribing information (Zadaxin). Always work with a qualified provider.

| Parameter | Detail |
|-----------|--------|
| **Standard dose** | 1.6 mg subcutaneous injection |
| **Frequency** | Twice weekly (typically Mon/Thu or Tue/Fri) |
| **Route** | Subcutaneous (upper arm, abdomen, or thigh) |
| **Cycle length** | 6 months for hepatitis B (approved use) |
| **Cancer adjuvant** | Variable; typically throughout chemo cycles |
| **Immune support** | 2-3 months in most research protocols |

### Dosing Variations in Research

| Application | Dose | Schedule | Duration |
|------------|------|----------|----------|
| **Hepatitis B (approved)** | 1.6 mg | Twice weekly | 6-12 months |
| **Cancer adjuvant** | 1.6 mg | Twice weekly | Duration of chemo |
| **Sepsis (clinical trial)** | 1.6 mg | Daily x 7 days | Acute phase |
| **COVID-19 (research)** | 1.6 mg | Daily x 5-7 days | Acute phase |
| **General immune support** | 1.6 mg | 2-3x per week | 8-12 weeks |

The **1.6 mg dose is remarkably consistent** across nearly all studies. Unlike many peptides where dose-finding is ongoing, Ta1 dosing has been standardized for decades.

### Reconstitution

Ta1 typically comes as a lyophilized powder. For reconstitution instructions, see our [guide to reconstituting peptides](/articles/how-to-reconstitute-peptides).

## Side Effects

Ta1 has one of the cleanest safety profiles of any injectable peptide in clinical use. Decades of data across thousands of patients support this.

### Common

| Side Effect | Frequency | Notes |
|-------------|-----------|-------|
| **Injection site discomfort** | Occasional | Mild redness or irritation, resolves quickly |
| **Mild fatigue** | Uncommon | Usually first few doses only |
| **Low-grade fever** | Rare | Sign of immune activation, typically transient |

### Uncommon

| Side Effect | Frequency | Notes |
|-------------|-----------|-------|
| **Muscle aches** | Rare | Flu-like symptoms in first week |
| **Nausea** | Very rare | Typically mild |
| **Allergic reaction** | Extremely rare | Fewer than 1% across all trials |

> **Key Finding:** In a pooled safety analysis of over 4,400 patients across clinical trials, Ta1 showed no significant difference in adverse events compared to placebo. ([Tuthill et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20590374/))

### When to Stop

- **Severe allergic reaction** - swelling, difficulty breathing, seek medical attention immediately
- **Autoimmune flare** - if you have an existing autoimmune condition that worsens, discontinue and consult your provider
- **Persistent fever above 101F** - may indicate infection rather than immune activation

For a broader overview, see our [peptide side effects guide](/articles/peptide-side-effects-what-to-know).

## Thymosin Alpha-1 vs. Other Immune Peptides

| Feature | Thymosin Alpha-1 | BPC-157 | Thymosin Beta-4 |
|---------|-----------------|---------|-----------------|
| **Primary action** | Immune modulation | Tissue repair / gut healing | Tissue repair / anti-inflammatory |
| **Immune effects** | Direct T-cell activation | Indirect (via gut health) | Mild anti-inflammatory |
| **Approved anywhere** | Yes (35+ countries) | No | No |
| **Clinical trial data** | Extensive (thousands of patients) | Limited (mostly animal) | Moderate |
| **Safety data** | Decades of human use | Limited human data | Moderate human data |
| **Best for** | Immune deficiency, infections, cancer support | Gut issues, injury healing | Wound healing, recovery |

## Who Might Benefit

Based on existing clinical data and approved uses:

- **Chronic hepatitis B patients** - the primary approved indication worldwide
- **Cancer patients undergoing chemotherapy** - to maintain immune function during treatment
- **Elderly individuals with immunosenescence** - declining immune function with age
- **Patients with recurrent infections** - those with documented low T-cell counts
- **Post-surgical patients** - to reduce infection risk and support recovery

> **Important:** Ta1 is not recommended as a casual immune booster for healthy individuals. Its greatest benefit appears in people with measurably compromised immune function.

## Legal Status and Availability

The regulatory status of Ta1 varies significantly by region.

| Region | Status |
|--------|--------|
| **United States** | Not FDA-approved. Available through compounding pharmacies with a prescription. Also sold as a research peptide. |
| **China** | Approved (Zadaxin). Widely used in hospitals. |
| **Italy** | Approved for compassionate use in certain conditions. |
| **India** | Approved and manufactured by multiple companies. |
| **Australia** | Not TGA-approved. Available through Special Access Scheme. |
| **35+ countries** | Approved as Zadaxin for hepatitis B and/or immune support. |

### Why Isn't It FDA-Approved?

The FDA requires large, well-controlled phase 3 trials conducted under US regulatory standards. SciClone Pharmaceuticals pursued most of its clinical development in Asia, where regulatory pathways differ.

The company reportedly explored FDA approval but determined the cost of US-specific trials (estimated at $100M+) wasn't justified given the relatively low price point of the drug. Generic competition in Asia further reduced the financial incentive.

### US Access

American patients can access Ta1 through:

- **Compounding pharmacies** with a physician's prescription
- **Research peptide suppliers** (for research use only)
- **Clinical trials** (limited availability)

Check our [peptide legality guide](/articles/are-peptides-legal-fda-regulations-2026) for full details.

## Frequently Asked Questions

### What does thymosin alpha-1 do?

Ta1 modulates your immune system by activating dendritic cells and promoting T-cell maturation. It increases CD4+ and CD8+ T-cell counts, enhances NK cell activity, and improves the body's ability to fight viral infections and detect cancerous cells.

It's not an immune stimulant in the traditional sense. It restores and optimizes immune function rather than simply ramping everything up.

### How long does it take to work?

Most clinical trials show measurable changes in T-cell counts within **1-2 weeks** of starting treatment. Viral load reductions in hepatitis patients typically appear by **4-8 weeks**, with full response assessed at **6 months**.

For general immune support, most practitioners recommend a minimum **8-week course** to evaluate response.

### Is thymosin alpha-1 safe?

By injectable peptide standards, Ta1 has an exceptionally strong safety record. Over 4,400 patients in clinical trials showed adverse event rates comparable to placebo.

It's been used clinically for over 25 years in dozens of countries. Serious adverse events are extremely rare.

That said, anyone with an active autoimmune condition should use caution, since enhanced immune function could theoretically worsen autoimmune flares.

### Can I combine thymosin alpha-1 with other peptides?

Ta1 is commonly combined with:

- **Thymosin beta-4 (TB-500)** - for combined immune and tissue repair benefits
- **BPC-157** - for gut healing alongside immune support
- **Interferon-alpha** - in approved hepatitis treatment protocols

Always discuss combinations with a healthcare provider, particularly if you're on immunosuppressive medications.

### Is thymosin alpha-1 the same as thymosin beta-4?

No. They're completely different peptides with different functions.

- **Thymosin alpha-1** (28 amino acids) is primarily an immune modulator
- **Thymosin beta-4** (43 amino acids) is primarily involved in tissue repair and wound healing

Both were originally isolated from thymic tissue, but they act through entirely different mechanisms.

### Can thymosin alpha-1 help with long COVID?

Some practitioners are using Ta1 off-label for long COVID, based on the hypothesis that persistent immune dysregulation drives ongoing symptoms. A few small case series have reported improvement in fatigue and cognitive symptoms.

But no controlled trials exist for this indication. The evidence is anecdotal at this point.

### Does thymosin alpha-1 have anti-aging effects?

The thymus shrinks with age (a process called thymic involution), and T-cell production declines accordingly. Ta1 can partially compensate for this decline by promoting T-cell maturation through alternative pathways.

Whether this translates to meaningful anti-aging benefits is speculative. Improved immune surveillance could theoretically reduce infection risk and cancer incidence in older adults, but long-term studies in healthy elderly populations haven't been conducted.

## The Bottom Line

Thymosin alpha-1 is one of the few peptides with genuine, large-scale clinical evidence behind it. Approved in over 35 countries, studied in thousands of patients, and used clinically for over two decades, it has a track record that most peptides can only dream of.

Its strongest applications remain in hepatitis B treatment, cancer immunotherapy support, and acute immune restoration in critically ill patients. The COVID-19 data added another layer of interest, though randomized trials are still needed.

For healthy individuals, Ta1 is probably unnecessary. Your immune system works fine. But for those with documented immune deficiency, chronic infections, or undergoing treatments that suppress immune function, it's one of the best-supported options available.

The biggest limitation? It's not FDA-approved, which limits access in the US and means insurance won't cover it. That's a regulatory and economic problem, not a scientific one.

**Related reading:**
- [What Are Peptides? Beginner's Guide](/articles/what-are-peptides-beginners-guide)
- [Peptide Side Effects: What to Know](/articles/peptide-side-effects-what-to-know)
- [Are Peptides Legal? FDA Regulations in 2026](/articles/are-peptides-legal-fda-regulations-2026)

For compound profiles and sourcing info, visit [PeptideArc](https://peptidearc.com).
